 David Moreno
Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Waldenstrom Macroglobulinemia | 4 | 2023 | 11 | 2.670 |
Why?
| | Lymphoma, B-Cell | 3 | 2023 | 86 | 2.320 |
Why?
| | Saccharomyces cerevisiae Proteins | 10 | 2023 | 333 | 2.060 |
Why?
| | Saccharomyces cerevisiae | 11 | 2023 | 476 | 1.960 |
Why?
| | Monoclonal Gammopathy of Undetermined Significance | 3 | 2023 | 3 | 1.900 |
Why?
| | Multiple Myeloma | 5 | 2022 | 93 | 1.450 |
Why?
| | Proteostasis | 2 | 2020 | 20 | 1.370 |
Why?
| | Molecular Chaperones | 3 | 2019 | 157 | 1.330 |
Why?
| | Cellular Senescence | 2 | 2020 | 152 | 1.250 |
Why?
| | Plasmacytoma | 2 | 2022 | 9 | 1.010 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2022 | 26 | 0.810 |
Why?
| | Calcaneus | 1 | 2022 | 57 | 0.770 |
Why?
| | Pharmaceutical Preparations | 2 | 2020 | 165 | 0.770 |
Why?
| | Myeloid Differentiation Factor 88 | 4 | 2023 | 90 | 0.760 |
Why?
| | Sarcoma, Ewing | 1 | 2022 | 64 | 0.750 |
Why?
| | Galactokinase | 1 | 2020 | 4 | 0.730 |
Why?
| | Automation | 1 | 2020 | 73 | 0.710 |
Why?
| | Epistasis, Genetic | 1 | 2020 | 67 | 0.700 |
Why?
| | Cell Enlargement | 2 | 2019 | 5 | 0.700 |
Why?
| | DNA Replication | 2 | 2023 | 202 | 0.690 |
Why?
| | Bone Neoplasms | 1 | 2022 | 194 | 0.690 |
Why?
| | High-Throughput Screening Assays | 2 | 2020 | 123 | 0.690 |
Why?
| | Graft vs Host Disease | 2 | 2019 | 212 | 0.670 |
Why?
| | G1 Phase Cell Cycle Checkpoints | 1 | 2019 | 8 | 0.660 |
Why?
| | Cell Cycle Checkpoints | 1 | 2019 | 84 | 0.650 |
Why?
| | Cell Size | 1 | 2019 | 80 | 0.640 |
Why?
| | Histone Deacetylases | 1 | 2020 | 195 | 0.640 |
Why?
| | Heat-Shock Response | 1 | 2019 | 46 | 0.640 |
Why?
| | Time-Lapse Imaging | 1 | 2019 | 19 | 0.630 |
Why?
| | Intravital Microscopy | 1 | 2019 | 23 | 0.630 |
Why?
| | Chromatin | 1 | 2020 | 428 | 0.560 |
Why?
| | Hematopoietic Stem Cell Transplantation | 2 | 2020 | 520 | 0.550 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2019 | 683 | 0.470 |
Why?
| | Cyclins | 4 | 2021 | 78 | 0.400 |
Why?
| | Smoldering Multiple Myeloma | 2 | 2021 | 2 | 0.390 |
Why?
| | Immunoglobulin M | 3 | 2022 | 246 | 0.380 |
Why?
| | Receptors, CXCR4 | 2 | 2022 | 78 | 0.360 |
Why?
| | CDC28 Protein Kinase, S cerevisiae | 2 | 2021 | 7 | 0.350 |
Why?
| | Mutation | 4 | 2023 | 3345 | 0.320 |
Why?
| | HSP40 Heat-Shock Proteins | 2 | 2019 | 21 | 0.300 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2022 | 636 | 0.290 |
Why?
| | Protein Biosynthesis | 4 | 2022 | 385 | 0.280 |
Why?
| | Gene Expression Regulation, Fungal | 3 | 2023 | 59 | 0.270 |
Why?
| | Cell Cycle | 3 | 2023 | 542 | 0.230 |
Why?
| | Disease-Free Survival | 2 | 2022 | 620 | 0.210 |
Why?
| | Prognosis | 2 | 2022 | 3327 | 0.210 |
Why?
| | Cell Cycle Proteins | 2 | 2023 | 551 | 0.200 |
Why?
| | Molecular Dynamics Simulation | 2 | 2020 | 201 | 0.200 |
Why?
| | Immunoglobulin Light-chain Amyloidosis | 1 | 2021 | 4 | 0.200 |
Why?
| | Humans | 18 | 2023 | 114654 | 0.190 |
Why?
| | Peptide Elongation Factor 1 | 1 | 2021 | 8 | 0.190 |
Why?
| | Allografts | 1 | 2022 | 122 | 0.190 |
Why?
| | Immunoglobulin Light Chains | 1 | 2021 | 35 | 0.190 |
Why?
| | Immunoglobulin Heavy Chains | 1 | 2021 | 72 | 0.190 |
Why?
| | Dendritic Spines | 1 | 2021 | 49 | 0.180 |
Why?
| | Genes, Regulator | 1 | 2020 | 34 | 0.180 |
Why?
| | Cytoplasmic Granules | 1 | 2021 | 82 | 0.180 |
Why?
| | Hydroxamic Acids | 1 | 2020 | 80 | 0.180 |
Why?
| | Niacinamide | 1 | 2020 | 63 | 0.180 |
Why?
| | Bone Marrow | 1 | 2021 | 243 | 0.180 |
Why?
| | Calibration | 1 | 2020 | 125 | 0.170 |
Why?
| | Feedback, Physiological | 1 | 2020 | 68 | 0.170 |
Why?
| | Epigenomics | 1 | 2020 | 101 | 0.170 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2022 | 858 | 0.170 |
Why?
| | Small Molecule Libraries | 1 | 2020 | 79 | 0.170 |
Why?
| | Immunotherapy, Adoptive | 1 | 2021 | 184 | 0.170 |
Why?
| | Polymerase Chain Reaction | 1 | 2022 | 993 | 0.170 |
Why?
| | Drug Discovery | 1 | 2020 | 123 | 0.170 |
Why?
| | Photopheresis | 1 | 2019 | 9 | 0.170 |
Why?
| | S Phase Cell Cycle Checkpoints | 1 | 2019 | 5 | 0.160 |
Why?
| | Cell Nucleolus | 1 | 2019 | 17 | 0.160 |
Why?
| | Acute Disease | 2 | 2019 | 910 | 0.160 |
Why?
| | Actins | 1 | 2021 | 381 | 0.160 |
Why?
| | Luminescent Agents | 1 | 2019 | 7 | 0.160 |
Why?
| | Gene Regulatory Networks | 1 | 2020 | 228 | 0.160 |
Why?
| | Spatio-Temporal Analysis | 1 | 2019 | 25 | 0.160 |
Why?
| | Lymphoma | 1 | 2020 | 177 | 0.160 |
Why?
| | Cyclin G1 | 1 | 2018 | 1 | 0.160 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2019 | 61 | 0.160 |
Why?
| | Cell Growth Processes | 1 | 2018 | 51 | 0.160 |
Why?
| | Genomics | 1 | 2023 | 635 | 0.160 |
Why?
| | Spectrometry, Fluorescence | 1 | 2019 | 157 | 0.150 |
Why?
| | Cyclin-Dependent Kinases | 1 | 2019 | 111 | 0.150 |
Why?
| | Centromere | 1 | 2018 | 42 | 0.150 |
Why?
| | Adenosine Triphosphatases | 1 | 2019 | 153 | 0.150 |
Why?
| | Stress, Physiological | 1 | 2021 | 378 | 0.150 |
Why?
| | Luminescent Proteins | 1 | 2019 | 166 | 0.150 |
Why?
| | Models, Molecular | 2 | 2020 | 1369 | 0.150 |
Why?
| | Models, Biological | 2 | 2021 | 1620 | 0.140 |
Why?
| | Skin Diseases | 1 | 2018 | 122 | 0.140 |
Why?
| | Pleural Effusion | 1 | 2017 | 47 | 0.140 |
Why?
| | Biological Evolution | 1 | 2020 | 416 | 0.140 |
Why?
| | Epigenesis, Genetic | 1 | 2020 | 520 | 0.130 |
Why?
| | Chronic Disease | 2 | 2019 | 1578 | 0.130 |
Why?
| | Antibodies, Monoclonal | 1 | 2022 | 1262 | 0.130 |
Why?
| | Recombinant Proteins | 1 | 2019 | 1230 | 0.130 |
Why?
| | Dexamethasone | 1 | 2017 | 317 | 0.120 |
Why?
| | Endoplasmic Reticulum | 1 | 2017 | 234 | 0.120 |
Why?
| | Diagnosis, Differential | 1 | 2018 | 1342 | 0.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2022 | 1355 | 0.120 |
Why?
| | Glucocorticoids | 1 | 2017 | 532 | 0.100 |
Why?
| | Incidence | 1 | 2018 | 2312 | 0.100 |
Why?
| | Signal Transduction | 2 | 2022 | 4512 | 0.100 |
Why?
| | T-Lymphocytes | 1 | 2018 | 1737 | 0.090 |
Why?
| | Transplantation, Autologous | 2 | 2022 | 176 | 0.090 |
Why?
| | Molecular Conformation | 2 | 2020 | 135 | 0.090 |
Why?
| | Antineoplastic Agents | 1 | 2019 | 1879 | 0.080 |
Why?
| | Male | 6 | 2022 | 55579 | 0.070 |
Why?
| | Middle Aged | 5 | 2021 | 26732 | 0.060 |
Why?
| | Adolescent | 1 | 2022 | 17837 | 0.060 |
Why?
| | Basic-Leucine Zipper Transcription Factors | 1 | 2023 | 39 | 0.050 |
Why?
| | Child | 1 | 2022 | 18407 | 0.050 |
Why?
| | Aged | 4 | 2021 | 19068 | 0.050 |
Why?
| | Longevity | 1 | 2023 | 137 | 0.050 |
Why?
| | Biological Transport | 1 | 2023 | 373 | 0.050 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2022 | 133 | 0.050 |
Why?
| | Iron | 1 | 2023 | 233 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2021 | 4411 | 0.050 |
Why?
| | Cytotoxicity, Immunologic | 1 | 2021 | 195 | 0.050 |
Why?
| | Intrinsically Disordered Proteins | 1 | 2021 | 15 | 0.050 |
Why?
| | Cellular Microenvironment | 1 | 2021 | 78 | 0.050 |
Why?
| | Trans-Activators | 1 | 2023 | 367 | 0.050 |
Why?
| | History, 21st Century | 1 | 2021 | 159 | 0.050 |
Why?
| | Neoplasm Grading | 1 | 2021 | 242 | 0.050 |
Why?
| | Aged, 80 and over | 2 | 2021 | 6345 | 0.040 |
Why?
| | Actin Cytoskeleton | 1 | 2021 | 93 | 0.040 |
Why?
| | History, 20th Century | 1 | 2021 | 264 | 0.040 |
Why?
| | Databases, Protein | 1 | 2020 | 59 | 0.040 |
Why?
| | Immunoglobulin A | 1 | 2021 | 166 | 0.040 |
Why?
| | Female | 6 | 2021 | 59488 | 0.040 |
Why?
| | Carcinogenesis | 1 | 2021 | 177 | 0.040 |
Why?
| | Molecular Weight | 1 | 2020 | 331 | 0.040 |
Why?
| | Quantum Theory | 1 | 2020 | 78 | 0.040 |
Why?
| | Blood Viscosity | 1 | 2019 | 16 | 0.040 |
Why?
| | Mortality | 1 | 2021 | 287 | 0.040 |
Why?
| | Proteasome Inhibitors | 1 | 2019 | 40 | 0.040 |
Why?
| | Neuronal Plasticity | 1 | 2021 | 209 | 0.040 |
Why?
| | Anti-Bacterial Agents | 2 | 2020 | 1481 | 0.040 |
Why?
| | HeLa Cells | 1 | 2021 | 562 | 0.040 |
Why?
| | Antibiotic Prophylaxis | 1 | 2020 | 96 | 0.040 |
Why?
| | Repressor Proteins | 1 | 2022 | 366 | 0.040 |
Why?
| | Rituximab | 1 | 2019 | 150 | 0.040 |
Why?
| | Ligands | 1 | 2020 | 561 | 0.040 |
Why?
| | Survival Analysis | 1 | 2021 | 1211 | 0.040 |
Why?
| | G1 Phase | 1 | 2018 | 68 | 0.040 |
Why?
| | Saccharomycetales | 1 | 2018 | 14 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2021 | 1167 | 0.040 |
Why?
| | Piperidines | 1 | 2019 | 160 | 0.040 |
Why?
| | Proteolysis | 1 | 2018 | 142 | 0.040 |
Why?
| | Computational Biology | 1 | 2021 | 530 | 0.040 |
Why?
| | Adenine | 1 | 2019 | 219 | 0.040 |
Why?
| | Disease Management | 1 | 2021 | 560 | 0.040 |
Why?
| | Immunoglobulin G | 1 | 2021 | 770 | 0.040 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2021 | 1139 | 0.030 |
Why?
| | Cell Division | 1 | 2018 | 758 | 0.030 |
Why?
| | Pyrimidines | 1 | 2019 | 376 | 0.030 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2021 | 1141 | 0.030 |
Why?
| | Pyrazoles | 1 | 2019 | 362 | 0.030 |
Why?
| | Membrane Glycoproteins | 1 | 2018 | 430 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1528 | 0.030 |
Why?
| | Databases, Factual | 1 | 2020 | 1125 | 0.030 |
Why?
| | Protein Binding | 1 | 2021 | 1889 | 0.030 |
Why?
| | Biomarkers, Tumor | 1 | 2021 | 1040 | 0.030 |
Why?
| | Community-Acquired Infections | 1 | 2017 | 141 | 0.030 |
Why?
| | Survival Rate | 1 | 2019 | 1644 | 0.030 |
Why?
| | C-Reactive Protein | 1 | 2017 | 362 | 0.030 |
Why?
| | Disease Progression | 1 | 2021 | 2380 | 0.030 |
Why?
| | Proteins | 1 | 2020 | 908 | 0.030 |
Why?
| | Gene Expression | 1 | 2019 | 1421 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2017 | 951 | 0.030 |
Why?
| | Nuclear Proteins | 1 | 2018 | 591 | 0.030 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1075 | 0.030 |
Why?
| | Phenotype | 1 | 2021 | 2796 | 0.030 |
Why?
| | RNA, Messenger | 1 | 2021 | 2552 | 0.030 |
Why?
| | Neurons | 1 | 2021 | 1279 | 0.030 |
Why?
| | Recovery of Function | 1 | 2017 | 574 | 0.030 |
Why?
| | Double-Blind Method | 1 | 2017 | 1660 | 0.030 |
Why?
| | Cohort Studies | 1 | 2021 | 4895 | 0.020 |
Why?
| | Pneumonia | 1 | 2017 | 567 | 0.020 |
Why?
| | Prospective Studies | 1 | 2021 | 6217 | 0.020 |
Why?
| | Time Factors | 1 | 2017 | 6115 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2019 | 9087 | 0.020 |
Why?
| | Child, Preschool | 1 | 2017 | 9111 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2019 | 12544 | 0.010 |
Why?
| | Adult | 1 | 2021 | 30542 | 0.010 |
Why?
|
|
Moreno's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|